On August 31, the influenza A H1N1 flu vaccine produced by Beijing Kexing Biological Products Co., Ltd. was approved and officially put into production for human vaccination. The hens are hatched for eggs from 9th to 10th (the eggs are cooked at this time), the virus is injected into the chicken, and the virus is officially cultured. After the injection, it is observed for 48-72 hours; August 31 The A-type H1N1 influenza vaccine produced by Beijing Kexing Biological Products Co., Ltd. was approved and officially put into production for human vaccination. The H1N1 influenza vaccine produced by Zhejiang Tianyuan Biopharmaceutical Co., Ltd. in Yuhang, Hangzhou has also passed the expert review.
The Ministry of Science and Technology launched the “H1N1 Influenza Joint Prevention and Control Emergency Research Project†and established a strategic alliance for influenza vaccine technology innovation. There are 9 companies producing vaccines, including Beijing Kexing and Zhejiang Tianyuan.
* Batch preparation of 120,000 ml vaccination
Yesterday, Ms. Huo Haiqin from the Quality Assurance Department of Zhejiang Tianyuan Biopharmaceutical Co., Ltd. asked her to talk about the process of producing vaccines -
First, the virus is obtained. This strain is a virus isolated from the human body. This strain is supplied by the British Institute of Biological Products, a designated supplier of the World Health Organization.
The hens are hatched for eggs from 9th to 10th (the eggs are cooked at this time), and the virus is injected into the chicken embryo to form the chicken. The virus is cultured and observed for 48-72 hours after injection;
The production staff used lights to illuminate the eggs, observe the maturity and development of the chicken embryos, and remove the eggs that have cracks, cracked shells, and chickens that have died;
The chicken embryos in good condition are selected and placed in an ice storage at 2 ° C - 8 ° C for about 8 days to allow the virus to multiply in the chicken embryos;
Then harvest the virus: open the chicken embryo, and like the egg, take out the juice from the egg - this is the virus solution;
The next step is the key step of removing the impurities in the virus solution by centrifugation, chemical extraction, etc. The first steps of each company producing the vaccine are the same, using different processes in this step;
At this time, the virus liquid is concentrated, and it is necessary to dilute the concentration in the human body.
Ms. Huo said that it is expected that the 120,000 ml vaccination produced by the company on Friday will be sent to the Drug Approval Center of the State Food and Drug Administration for testing. It is expected that Zui will be put on the market next week and start vaccination. In addition to the loss, the 120,000 ml vaccine can be used for approximately 190,000 people.
The vaccine can make people feel resistant
In November last year, Zhejiang Province carried out measles vaccine booster immunization across the province. At that time, Chen Enfu, director of the Institute of Immunology Prevention, Zhejiang Provincial Center for Disease Control and Prevention, explained the principle of the vaccine -
Vaccine is a live attenuated vaccine, which is to reduce the virus to a substantially non-toxic, re-implanted into the human body, artificially infected with the virus, allowing the virus to grow and reproduce in the human body. Vaccine viruses can cause the body to develop resistance to the virus.
"The concentration of the influenza A H1N1 flu vaccine should not be too high, otherwise it would be like taking a wolf into the room, and people should be seriously ill," said Huo Haiqin.
Zhejiang Tianyuan's A-type H1N1 flu vaccine has collected hundreds of volunteers, all over the age of 3, each with 0.5 ml of vaccine, no obvious adverse reactions after injection, only mild reactions such as redness and pain at the injection site .
The vaccine will give priority to the key population
Health Minister Chen Wei said that the influenza A (H1N1) flu vaccine will enter the vaccination stage, and the vaccination will be given to susceptible populations, such as people with basic diseases and workers in special fields.
The Zhejiang Provincial Health Department said that the order of vaccine use in Zhejiang Province will be based on the order of core population, high-risk groups, key populations and applicable populations. The core group refers to the relevant personnel who handle the epidemic; the high-risk groups include the immigration reception personnel, the epidemic prevention and control materials production personnel, and the medical staff who send out fever clinics and infectious clinics; the key population includes chronic patients and frail patients; the applicable population includes children, students, Old man.
The World Health Organization will track the evolution of the flu, disclose information in a timely manner, define who is at high risk for the flu, and let countries refer to those who decide to vaccinate first.
Stubble Rotary Crusher,50HP Stubble Rotary Crusher,Dual Shaft Crusher,Tractor Drived Stubble Rotary Crusher
Shandong Dahua Machinery Co.,Ltd , https://www.agrodahua.com